Mapping for Acute Transvenous Phrenc nerve Stimulation Study

Published: 30-01-2015 Last updated: 21-04-2024

Protocol page 17The Mapping for Transvenous Phrenic Nerve Stimulation Study (MAPS) is being conducted to evaluate the feasibility of transvascular stimulation of phrenic nerves via an EP catheter advanced into the great veins.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Sleep disturbances (incl subtypes)
Study type	Interventional

Summary

ID

NL-OMON41783

Source ToetsingOnline

Brief title MAPS Study

Condition

• Sleep disturbances (incl subtypes)

Synonym Sleep apnea

Research involving Human

Sponsors and support

Primary sponsor: Medtronic Source(s) of monetary or material Support: Medtronic

Intervention

Keyword: Phrenic Nerve, Sleep apnea, Stimulation, Transvenous

Outcome measures

Primary outcome

Protocol page 17

To evaluate the feasibility of acute transvenous electrical stimulation of the phrenic nerves to elicit diaphragm movement in patients undergoing a cardiac catheterization involving right heart catheterization and/or EP procedures and/or device implant, as measured by the proportion patients responding.

Secondary outcome

Protocol page 17 and 18

Evaluate the feasibility of acute transvenous electrical stimulation of the phrenic nerves to elicit inspiration in patients undergoing a cardiac catheterization involving right heart catheterization and/or EP procedures and/or device implant, as measured by the proportion patients responding.

Characterize 1) diaphragm movement and if feasible 2) inspiratory response to changes on stimulation parameters (electrode configuration, amplitude, frequency, and pulse width).For each of the tested anatomical positions, the proportion of patients with capture will be plotted as function of the stimulation parameters (electrode configuration, amplitude, frequency, and pulse width).

2 - Mapping for Acute Transvenous Phrenc nerve Stimulation Study 30-05-2025

Characterize other potential physiologic changes or side effects associated with transvenous nerve stimulation. All observed side effects like potential physiologic changes or side effects associated with transvenous nerve stimulation such as pain, hiccup, skeletal muscular tremor, nausea, sinus node activation will be listed, with number of patients in which the effect was seen. For side effects that appeared frequently, the relation with stimulation position and parameters will be investigated.

Study description

Background summary

Protocol page 14

Approximately 100 million individuals are suffering from moderate-to-severe obstructive sleep apnea (OSA) worldwide. In addition, there is a significant overlap between sleep apnea patients and cardiovascular disease; such as heart failure, atrial fibrillation, and bradycardia To treat sleep apnea in heart failure patients a possible solution could be the extension of leads (which are placed with the tip intra-cardially) with intravenous electrodes.

Study objective

Protocol page 17

The Mapping for Transvenous Phrenic Nerve Stimulation Study (MAPS) is being conducted to evaluate the feasibility of transvascular stimulation of phrenic nerves via an EP catheter advanced into the great veins.

Study design

Protocol page 18

This is a prospective, non*randomized, acute feasibility study.

Intervention

Protocol page 17

Phrenic nerve stimulation

Study burden and risks

Protocol page 47 and 48

The potential risks to a subject participating in this study are believed to be similar to those encountered during EP procedures, right heart catheterization procedures, and device implants.

These include, but are not limited to, the following:

* Electrical current leakage

* Infection

* Injury to the heart or major blood vessels due to direct contact of EP catheter.

* Pain from stimulation of nerves and/or muscles located in the region of the great veins

* A blood clot in the heart, lung, or veins.

Contacts

Public Medtronic

Endepolsdomein 5 Maastricht 6229GW NL Scientific Medtronic

Endepolsdomein 5 Maastricht 6229GW NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Subject is undergoing a cardiac catheterization involving right heart catheterization and/or EP procedures and/or device implant.

Exclusion criteria

Subject with a previously implanted transvenous lead, which is still present in the veins under study. Subject with evidence of phrenic nerve palsy. Subject with chronic obstructive pulmonary disease. Subject with a spinal cord stimulator.

Study design

Design

Study type: Interventional		
Masking:	Open (masking not used)	
Control:	Uncontrolled	
Primary purpose:	Other	
Recruitment		
NL		
Recruitment status:	Recruitment stopped	
Start date (anticipated):	24-11-2014	
Enrollment:	15	
Туре:	Actual	

Medical products/devices used

Generic name:	Zie protocol pagina 12;15;16 en 17
Registration:	Yes - CE outside intended use

Ethics review

Approved WMO	
Date:	3
Application type:	F
Review commission:	Ν
	/

30-01-2015 First submission MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ClinicalTrials.gov CCMO ID NCT01981590 NL51098.060.14